首页> 外文OA文献 >Risk Factors for Acquired Rifamycin and Isoniazid resistance: A systematic review and meta-analysis
【2h】

Risk Factors for Acquired Rifamycin and Isoniazid resistance: A systematic review and meta-analysis

机译:获得性利福霉素和异烟肼耐药性的危险因素:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Studies looking at acquired drug resistance (ADR) are diverse with respect to geographical distribution, HIV co-infection rates, retreatment status and programmatic factors such as regimens administered and directly observed therapy. Our objective was to examine and consolidate evidence from clinical studies of the multifactorial aetiology of acquired rifamycin and/or isoniazid resistance within the scope of a single systematic review. This is important to inform policy and identify key areas for further studies. METHODS: Case-control and cohort studies and randomised controlled trials that reported ADR as an outcome during antitubercular treatment regimens including a rifamycin and examined the association of at least 1 risk factor were included. Post hoc, we carried out random effects Mantel-Haenszel weighted meta-analyses of the impact of 2 key risk factors 1) HIV and 2) baseline drug resistance on the binary outcome of ADR. Heterogeneity was assessed used I 2 statistic. As a secondary outcome, we calculated median cumulative incidence of ADR, weighted by the sample size of the studies. RESULTS: Meta-analysis of 15 studies showed increased risk of ADR with baseline mono- or polyresistance (RR 4.85 95% CI 3.26 to 7.23, heterogeneity I 2 58%, 95% CI 26 to 76%). Meta-analysis of 8 studies showed that HIV co-infection was associated with increased risk of ADR (RR 3.02, 95% CI 1.28 to 7.11); there was considerable heterogeneity amongst these studies (I 2 81%, 95% CI 64 to 90%). Non-adherence, extrapulmonary/disseminated disease and advanced immunosuppression in HIV co-infection were other risk factors noted. The weighted median cumulative incidence of acquired multi drug resistance calculated in 24 studies (assuming whole cohort as denominator, regardless of follow up DST) was 0.1% (5 th to 95 th percentile 0.07 to 3.2%). CONCLUSION: Baseline drug resistance and HIV co-infection were significant risk factors for ADR. There was a trend of positive association with non-adherence which is likely to contribute to the outcome of ADR. The multifactorial aetiology of ADR in a programmatic setting should be further evaluated via appropriately designed studies.
机译:背景:关于获得性抗药性(ADR)的研究在地理分布,HIV合并感染率,再治疗状态和程序性因素(例如所用治疗方案和直接观察到的治疗)方面是多种多样的。我们的目标是在单一系统评价的范围内,检查和巩固来自获得性利福霉素和/或异烟肼耐药性多因素病因学的临床研究证据。这对于制定政策并确定需要进一步研究的关键领域非常重要。方法:包括病例对照和队列研究以及随机对照试验,这些试验报告了ADR作为包括利福霉素在内的抗结核治疗方案的结果,并检查了至少一种危险因素的相关性。事后,我们对2个主要危险因素1)HIV和2)基线耐药性对ADR的二元结果的影响进行了Mantel-Haenszel加权荟萃分析。使用I 2统计量评估异质性。作为次要结果,我们计算了ADR的中位数累积发生率,并按研究的样本量加权。结果:对15项研究的荟萃分析显示,基线单抗或多药耐药的ADR风险增加(RR 4.85 95%CI 3.26至7.23,异质性I 2 58%,95%CI 26至76%)。对8项研究的荟萃分析显示,HIV合并感染与ADR风险增加相关(RR 3.02,95%CI 1.28至7.11);这些研究之间存在相当大的异质性(I 2 81%,95%CI 64至90%)。注意到HIV合并感染中的非依从性,肺外/弥漫性疾病和晚期免疫抑制是其他危险因素。在24项研究中计算得出的获得性多药耐药性的加权中位数累积发生率(假设整个队列为分母,而不考虑随访DST)为0.1%(第5至95个百分位数为0.07至3.2%)。结论:基线耐药性和HIV合并感染是ADR的重要危险因素。与不依从存在积极联系的趋势,这可能有助于ADR的结果。在程序化背景下,ADR的多因素病因应通过适当设计的研究进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号